Tests mesothelin-targeting CAR T cells in adults with solid tumors
Tests modified immune cells in adults with mesothelin-positive solid tumors that have lost HLA-A*02.
Key facts
- Who runs it
- A2 Biotherapeutics Inc.
- Where
- Columbus, Gilbert, Jacksonville, La Jolla, Los Angeles, Nashville, New York, Rochester, Seattle, St Louis, Stanford, and Tampa, United StatesSee the 12 sites
- Trial code
- Registry title
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 474 people, planned
- Started
- 3 Apr 2024
- Expected to end
- Jun 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- A2B694
- A2B543
- xT CDx with HLA-LOH Assay
- Record updated
- 12 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with solid tumors (such as colorectal, lung, pancreatic, ovarian cancer or mesothelioma) that have come back or spread, carry mesothelin (MSLN) and have lost HLA-A*02.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Recurrent, unresectable, locally advanced or metastatic solid tumor (CRC, NSCLC, PANC, OVCA, MESO or other) with measurable disease of 1.0 cm (0.4 in) or more on CT.
- Earlier treatment
- Must have received the previous therapy for the tumor that the protocol requires. Cancer therapy within 3 weeks or 3 half lives of infusion is not allowed. Radiotherapy within 28 days of infusion is not allowed.
- Biomarker or test result
- Tumor tissue shows loss of HLA-A*02 (LOH) by NGS, and the tumor expresses MSLN. Must be enrolled in the BASECAMP-1 study with successful apheresis and enough stored cells.
Main reasons for not taking part
- Disease that can be treated with local therapy or standard therapy that is therapeutic, not palliative
- Prior allogeneic stem cell transplant or prior solid organ transplant
- Significant heart disease within the last 6 months
- Needs oxygen at home, or has had interstitial lung disease needing prolonged steroids within 1 year
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy
- Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT
- Received previous required therapy for the appropriate solid tumor disease as described in the protocol
- Has adequate organ function as described in the protocol
- ECOG performance status of 0 to 1
- Life expectancy of ≥3 months
- Willing to comply with study schedule of assessments including long term safety follow up
Who cannot take part
- Prior allogeneic stem cell transplant
- Prior solid organ transplant
- Radiotherapy within 28 days of infusion
- History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year
- Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative
- Cancer therapy within 3 weeks or 3 half lives of infusion
- Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months
- Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated
- MESO with pleural involvement extending into the peritoneum
- Requires supplemental home oxygen
- Females of childbearing potential who are pregnant or breastfeeding
- Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion
Where in United States
- The Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Dudbeth BrownTaking people
- Banner HealthGilbert, United StatesContact: Yasmin AdamTaking people
- Mayo ClinicJacksonville, United StatesContact: Rhoda RomainTaking people
- UCSD Moores Cancer CenterLa Jolla, United StatesContact: Jona PlevinTaking people
- UCLA Medical CenterLos Angeles, United StatesContact: Nicole WilliamsTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)Taking people
- NYU Langone Medical CenterNew York, United StatesContact: Peter WarrenTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Teri Heddlesten RediskeTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Shelby ColdenTaking people
- Washington UniversitySt Louis, United StatesContact: Amberly ScottTaking people
- Stanford UniversityStanford, United StatesContact: Kayla McDanielTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Jarriaun StreetsTaking people
About the trial
What the trial wants to find out
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression.
Read full original descriptionShow less
The main questions this study aims to answer are:
Phase 1: What is the recommended dose that is safe for patients
Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells
Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:
Enrollment and Apheresis in BASECAMP-1 (NCT04981119)
Preconditioning Lymphodepletion (PCLD) Regimen
Tmod CAR T cells at the assigned dose
The 2 groups in the trial
- Arm 1: A2B694Treatment being tested
Patients receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B694 intravenously on day 0
Treatment: A2B694 and xT CDx with HLA-LOH Assay
- Arm 2: A2B543Treatment being tested
Patients receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B543 intravenously on day 0
Treatment: A2B543 and xT CDx with HLA-LOH Assay
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Plain-language title
- Tests mesothelin-targeting CAR T cells in adults with solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 June 2026